WKEY vs RNTX Comparison

WISeKey International Holding Ltd at the forefront of authentication and cybersecurity technology. It develops, markets, hosts, and supports a range of solutions that enable the secure digital identification and communication of people, content, and objects, by generating digital identities that enable its clients to monetize their existing user bases and, at the same time, expand their own eco-system securely by ensuring only authenticated objects and people can connect. The WISeKey Group operates through five core verticals: SEALSQ, WISeSat, SEALCOIN, WISeID, & WISe.ART. It has two business segments. Semiconductors & ASICs. The majority of its revenue is generated from the Semiconductors segment.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.